By demonstrating that hyperandrogenism leads to increased estrogen synthesis through AR-FOXL2-mediated activation of the aromatase gene in GCs, our study explains why the targeted inhibition of aromatase by letrozole is particularly effective in PCOS patients [70]. The gene discussed is CYP19A1; the disease is hyperandrogenism.